Dr. Mrug is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
700 19th St S
Birmingham, AL 35233Phone+1 205-933-8101Fax+1 205-933-4497- Is this information wrong?
Education & Training
- University of Alabama Medical CenterFellowship, Nephrology, 2002 - 2004
- USA HealthResidency, Internal Medicine, 1999 - 2002
- Karlovy University FOMClass of 1995
Certifications & Licensure
- AL State Medical License 2002 - 2022
- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase...Ronald T Gansevoort, Ali Hariri, Pascal Minini, Curie Ahn, Arlene B Chapman, Shigeo Horie, Bertrand Knebelmann, Michal Mrug, Albert Cm Ong, York Pc Pei, Vicente E Torr...> ;American journal of kidney diseases : the official journal of the National Kidney Foundation. 2022 Dec 16
- A kidney resident macrophage subset is a candidate biomarker for renal cystic disease in preclinical models.Zhang Li, Kurt A Zimmerman, Sreelakshmi Cherakara, Phillip H Chumley, James F Collawn, Jun Wang, Courtney J Haycraft, Cheng J Song, Teresa Chacana, Reagan S Andersen, ...> ;Disease models & mechanisms. 2023 Jan 1
- The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.Ronald D Perrone, Ali Hariri, Pascal Minini, Curie Ahn, Arlene B Chapman, Shigeo Horie, Bertrand Knebelmann, Michal Mrug, Albert C M Ong, York P C Pei, Vicente E Torre...> ;Kidney medicine. 2022 Oct 1
- Join now to see all
Journal Articles
- A Practical Guide for Treatment of Rapidly Progressive ADPKD with TolvaptanRonald D Perrone, Anjay Rastogi, Terry Watnick, Arlene B Chapman, Michal Mrug, Vicente E Torres, Fouad T Chebib, Neera K Dahl, Peter C Harris, Journal of the American Society of Nephrology
Authored Content
- Baseline Total Kidney Volume and the Rate of Kidney Growth Are Associated with Chronic Kidney Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseDecember 2017
Press Mentions
- Otsuka’s JYNARQUE™ (Tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)April 24th, 2018
Hospital Affiliations
- Birmingham Veterans Affairs Medical CenterBirmingham, Alabama
- University of Alabama HospitalBirmingham, Alabama
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: